MedPath

Kadmon Pharmaceuticals, LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

2

NMPA:1
FDA:1

Drug Approvals

Belumosudil Mesylate Tablets

Product Name
易来克
Approval Number
国药准字HJ20230095
Approval Date
Aug 1, 2023
NMPA

Clinical Trials

No trials found

News

Belumosudil Shows Promise in Treating Heavily Pretreated Chronic Graft-versus-Host Disease

Real-world data shows belumosudil is often used in combination after multiple prior therapies for chronic graft-versus-host disease (cGVHD).

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.